SG11202107317WA - Combinaton therapy with a don prodrug and an immune checkpoint inhibitor - Google Patents

Combinaton therapy with a don prodrug and an immune checkpoint inhibitor

Info

Publication number
SG11202107317WA
SG11202107317WA SG11202107317WA SG11202107317WA SG11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA
Authority
SG
Singapore
Prior art keywords
combinaton
therapy
immune checkpoint
checkpoint inhibitor
don prodrug
Prior art date
Application number
SG11202107317WA
Inventor
Robert Christian Wild
Thomas Estok
Original Assignee
Dracen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dracen Pharmaceuticals Inc filed Critical Dracen Pharmaceuticals Inc
Publication of SG11202107317WA publication Critical patent/SG11202107317WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202107317WA 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor SG11202107317WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794231P 2019-01-18 2019-01-18
PCT/US2020/014149 WO2020150639A1 (en) 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
SG11202107317WA true SG11202107317WA (en) 2021-08-30

Family

ID=71614516

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107317WA SG11202107317WA (en) 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20220117938A1 (en)
EP (1) EP3911310A4 (en)
JP (1) JP2022518232A (en)
KR (1) KR20210117303A (en)
CN (1) CN113438947A (en)
AU (1) AU2020208637A1 (en)
BR (1) BR112021014112A2 (en)
CA (1) CA3126822A1 (en)
EA (1) EA202191992A1 (en)
IL (1) IL284907A (en)
MX (1) MX2021008546A (en)
SG (1) SG11202107317WA (en)
WO (1) WO2020150639A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4037674A4 (en) * 2019-10-03 2023-10-25 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
WO2022022612A1 (en) * 2020-07-29 2022-02-03 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
US20230372294A1 (en) * 2020-10-02 2023-11-23 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof
CN114621120B (en) * 2020-12-10 2023-11-03 深圳先进技术研究院 DON prodrug molecule, prodrug activating compound and prodrug activating system
WO2022232565A1 (en) * 2021-04-29 2022-11-03 The Johns Hopkins University Prodrugs of 6-diazo-5-oxo-l-norleucine
WO2022261117A1 (en) * 2021-06-07 2022-12-15 Dracen Pharmaceuticals, Inc. Combination therapy with a don prodrug and a tigit inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
WO2017023793A2 (en) * 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
WO2017023774A1 (en) * 2015-07-31 2017-02-09 The Johns Hopkins University Prodrugs of glutamine analogs
WO2017040666A2 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
DK3692015T3 (en) * 2017-10-06 2022-11-21 Univ Johns Hopkins PREVIOUSLY UNKNOWN GLUTAMINE ANTAGONISTS AND USES THEREOF

Also Published As

Publication number Publication date
KR20210117303A (en) 2021-09-28
AU2020208637A1 (en) 2021-09-09
WO2020150639A1 (en) 2020-07-23
CA3126822A1 (en) 2020-07-23
EA202191992A1 (en) 2021-12-17
JP2022518232A (en) 2022-03-14
US20220117938A1 (en) 2022-04-21
EP3911310A1 (en) 2021-11-24
BR112021014112A2 (en) 2021-10-13
CN113438947A (en) 2021-09-24
IL284907A (en) 2021-09-30
MX2021008546A (en) 2021-11-12
EP3911310A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
IL284907A (en) Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
IL267617A (en) Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
ZA201900060B (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
IL283598A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL256148B (en) A cbp/catenin inhibitor and immune checkpoint inhibitor for use un treating cancer
IL265274A (en) Antibody and checkpoint inhibitor combination therapy
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL261584A (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
GB201913857D0 (en) Computing circuitry
IL292219A (en) Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
SG11202011261PA (en) Urolithin a and derivatives thereof for use in therapy
IL266521A (en) Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
IL261554B (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
LT3463436T (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
GB2583782B (en) Computing circuitry
IL261505A (en) Combination therapy using a liv1-adc and a chemotherapeutic
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
IL260185A (en) A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor
GB2575548B (en) A cycle and a dock
GB2588174B (en) A jig and use thereof
EP4082571A4 (en) Antitumor drug for use in combination with immune checkpoint inhibitor
IL262077A (en) A computer game for practicing linear equations
EP4076048C0 (en) An aerosol-generating article comprising a barrier
GB201902572D0 (en) Safety flooring substarte
ZA202001148B (en) Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor